Please use this identifier to cite or link to this item:
https://doi.org/10.1155/2015/308574
Title: | Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy | Authors: | Subhash, V.V Yeo, M.S Tan, W.L Yong, W.P |
Keywords: | antineoplastic agent cancer vaccine chimeric antigen receptor cytotoxic T lymphocyte antigen 4 dendritic cell vaccine durvalumab immunomodulating agent ipilimumab mpdl 3280a nivolumab pembrolizumab programmed death 1 ligand 1 T lymphocyte antigen ticilimumab tumor antigen cancer vaccine adaptive immunity adoptive immunotherapy adoptive transfer cancer immunization cancer immunotherapy cytotoxic T lymphocyte human immune evasion immune response immune system immunogenicity immunosurveillance innate immunity multicenter study (topic) natural killer cell phase 1 clinical trial (topic) phase 2 clinical trial (topic) randomized controlled trial (topic) Review stomach cancer T lymphocyte tumor associated leukocyte tumor microenvironment clinical trial (topic) immunity immunological memory immunological monitoring immunology immunotherapy procedures Stomach Neoplasms Cancer Vaccines Clinical Trials as Topic Humans Immune System Phenomena Immunologic Memory Immunotherapy Monitoring, Immunologic Stomach Neoplasms Tumor Microenvironment |
Issue Date: | 2015 | Citation: | Subhash, V.V, Yeo, M.S, Tan, W.L, Yong, W.P (2015). Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy. Journal of Immunology Research 2015 : 308574. ScholarBank@NUS Repository. https://doi.org/10.1155/2015/308574 | Abstract: | In cancer biology, cells and molecules that form the fundamental components of the tumor microenvironment play a major role in tumor initiation, and progression as well as responses to therapy. Therapeutic approaches that would enable and harness the immune system to target tumor cells mark the future of anticancer therapy as it could induce an immunological memory specific to the tumor type and further enhance tumor regression and relapse-free survival in cancer patients. Gastric cancer is one of the leading causes of cancer-related mortalities that has a modest survival benefit from existing treatment options. The advent of immunotherapy presents us with new approaches in gastric cancer treatment where adaptive cell therapies, cancer vaccines, and antibody therapies have all been used with promising outcomes. In this paper, we review the current advances and prospects in the gastric cancer immunotherapy. Special focus is laid on new strategies and clinical trials that attempt to enhance the efficacy of various immunotherapeutic modalities in gastric cancer. © 2015 Vinod Vijay Subhash et al. | Source Title: | Journal of Immunology Research | URI: | https://scholarbank.nus.edu.sg/handle/10635/176161 | ISSN: | 2314-8861 | DOI: | 10.1155/2015/308574 |
Appears in Collections: | Elements Staff Publications |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_1155_2015_308574.pdf | 2.64 MB | Adobe PDF | OPEN | None | View/Download |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.